Abstract
GSK-3 inhibitors are interesting candidates to develop anti-Alzheimer compounds. GSK-3β are also interesting as antiparasitic compounds active against Plasmodium falciparum, Trypanosoma brucei, and Leishmania donovani; the causative agents for Malaria, African Trypanosomiasis and Leishmaniosis. The high number of possible candidates creates the necessity of Quantitative Structure-Activity Relationship models in order to guide the GSK3 (Glycogen Synthase Kinase 3 inhibitor) synthesis. In this work, we revised different computational studies for a very large and heterogeneous series of GSK-3Is. First, we revised QSAR studies with conceptual parameters such as flexibility of rotation, probability of availability, etc. We then used the method of regression analysis and QSAR studies in order to understand the essential structural requirement for binding with receptor. Next, we reviewed 3D-QSAR, CoMFA and CoMSIA with different compounds to find out the structural requirements for GSK-3 inhibitory activity.
Keywords: QSAR, Alzheimer, SAR, parasitic, fungi, anti-Alzheimer compounds, GSK-3, Neurofibrillary tangles (NFTs), Docking, Thiadiazolidinone Derivatives, QSAR Modeling, Indirubin Analogues, Bisarylmaleimides, CDK-2, CDK-4, Image-Based Approach, Indirubin Derivatives, Multi-Target QSAR
Current Pharmaceutical Design
Title: QSAR, Docking, and CoMFA Studies of GSK3 Inhibitors
Volume: 16 Issue: 24
Author(s): Isela Garcia, Yagamare Fall and Generosa Gomez
Affiliation:
Keywords: QSAR, Alzheimer, SAR, parasitic, fungi, anti-Alzheimer compounds, GSK-3, Neurofibrillary tangles (NFTs), Docking, Thiadiazolidinone Derivatives, QSAR Modeling, Indirubin Analogues, Bisarylmaleimides, CDK-2, CDK-4, Image-Based Approach, Indirubin Derivatives, Multi-Target QSAR
Abstract: GSK-3 inhibitors are interesting candidates to develop anti-Alzheimer compounds. GSK-3β are also interesting as antiparasitic compounds active against Plasmodium falciparum, Trypanosoma brucei, and Leishmania donovani; the causative agents for Malaria, African Trypanosomiasis and Leishmaniosis. The high number of possible candidates creates the necessity of Quantitative Structure-Activity Relationship models in order to guide the GSK3 (Glycogen Synthase Kinase 3 inhibitor) synthesis. In this work, we revised different computational studies for a very large and heterogeneous series of GSK-3Is. First, we revised QSAR studies with conceptual parameters such as flexibility of rotation, probability of availability, etc. We then used the method of regression analysis and QSAR studies in order to understand the essential structural requirement for binding with receptor. Next, we reviewed 3D-QSAR, CoMFA and CoMSIA with different compounds to find out the structural requirements for GSK-3 inhibitory activity.
Export Options
About this article
Cite this article as:
Garcia Isela, Fall Yagamare and Gomez Generosa, QSAR, Docking, and CoMFA Studies of GSK3 Inhibitors, Current Pharmaceutical Design 2010; 16 (24) . https://dx.doi.org/10.2174/138161210792389225
DOI https://dx.doi.org/10.2174/138161210792389225 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioactive Compounds in Some Culinary Aromatic Herbs and Their Effects on Human Health
Mini-Reviews in Medicinal Chemistry Recent Advances in the Imaging of Programmed Cell Death
Current Pharmaceutical Design Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Human Tooth Germ Stem Cells Preserve Neuro-Protective Effects after Long-Term Cryo-Preservation
Current Neurovascular Research Non-Communicable Diseases and Adherence to Mediterranean Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Astroglial Connexins in Neurological and Neuropsychological Disorders and Radiation Exposure
Current Medicinal Chemistry Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science HIV-1 Subtypes B and C Tat Differentially Impact Synaptic Plasticity Expression and Implicates HIV-Associated Neurocognitive Disorders§
Current HIV Research Update on the Pharmacological Treatment of Alzheimers Disease
Current Neuropharmacology Association of Platelet Activation with Vascular Cognitive Impairment: Implications in Dementia Development?
Current Vascular Pharmacology Carotid Artery Disease: Current Concepts on Endothelial Dysfunction and Matrix Remodeling
Current Drug Therapy Chemical and Biological Aspects of the Natural 1,4-Benzoquinone Embelin and its (semi-)Synthetic Derivatives
Current Medicinal Chemistry Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches
Current Molecular Pharmacology New Targets for Treating the Underlying Pathophysiology and Nonmotor Aspects of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Editorial: Current Approaches in the Treatment of Neuropsychiatric Diseases
Current Topics in Medicinal Chemistry Oral GPIIb / IIIa Antagonists: What Went Wrong?
Current Pharmaceutical Design Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease
Current Medicinal Chemistry Sensitivity of Different MRI-Techniques to Assess Gray Matter Atrophy Patterns in Alzheimer’s Disease is Region-Specific
Current Alzheimer Research Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinsons Disease?
Current Genomics Acute Cellular Oxygen Sensing in the Heart - A Role for Mitochondria?
Vascular Disease Prevention (Discontinued)